Chiang, Chi-Lu
Lee, Cheng-Chia
Huang, Hsu-Ching
Wu, Chia-Hung
Yeh, Yi-Chen
Shen, Chia-I
Luo, Yung-Hung
Shiao, Tsu-Hui
Chang, Han Jhih
Huang, Yu-Ting
Chen, Yuh-Min
Chou, Teh-Ying
Chiu, Chao-Hua
Funding for this research was provided by:
Ministry of Science and Technology, Taiwan (MOST106-2314-B-075-031-MY)
Ministry of Health and Welfare (MOHW109-TDU-B-211-134019)
Taipei Veterans General Hospital (V110B-008)
Article History
Accepted: 11 January 2021
First Online: 10 February 2021
Declarations
:
: This work was supported by the Ministry of Science and Technology, Taiwan (Grant number MOST106-2314-B-075-031-MY), Ministry of Health and Welfare, Taiwan (Grant number MOHW109-TDU-B-211-134019), and Taipei Veterans General Hospital (Grant number V110B-008).
: CLC has received honoraria from AstraZeneca, Boehringer Ingelheim, and Roche. YHL has received honoraria from AstraZeneca, Boehringer Ingelheim, and Pfizer. THS has received honoraria from Boehringer Ingelheim and Novartis. YMC has received honoraria from Boehringer Ingelheim, Eli Lilly, Roche/Genentech/Chugai, MSD, Pfizer, Novartis, BMS, Ono Pharmaceutical, AstraZeneca, and Takeda Oncology; and served as advisor for Boehringer Ingelheim, Eli Lilly, Roche/Chugai, MSD, AstraZeneca, and Takeda Oncology. CHC has received honoraria from AstraZeneca, Boehringer Ingelheim, Pfizer, and Roche. The other authors declare no conflicts of interest that might be relevant to the contents of this article.
: The Institutional Review Board of Taipei Veterans General Hospital approved this study.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Conceptualization: CLC, CHC, YMC, TYC. Data collection, experiment, and analysis: CCL, CHW, HCH, YCY, CIS, YHL, THS. Statistics: CLC, HJC, YTH. First draft preparation: CLC, CHC. Review and final approval: all authors.